Study highlights side effects experienced by BRCA mutation carriers following cancer risk-reducing surgical procedure

May 30, 2014 by Katie Delach

The majority of women with cancer causing BRCA1 and BRCA2 mutations experience sexual dysfunction, menopausal symptoms, cognitive and stress issues, and poor sleep following prophylactic removal of their Fallopian tubes and ovaries - a procedure known as risk-reducing salpingo-oophorectomy (RRSO) - according to results of a new study from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania. The team's findings, which reaffirm the need for a better understanding of how to manage long-term effects of the risk-reducing procedure, will be presented during the annual meeting of the American Society of Clinical Oncology in Chicago's McCormick Place on Saturday, May 31, 2014 (abstract #1508).

"These results reinforce the need for care providers to better understand and communicate with patients about the possible long-term effects of bilateral RRSO," said lead author Susan Domchek, MD, director of Penn's Basser Research Center for BRCA. "Removal of the Fallopian tubes and ovaries is associated with a decreased risk of death from breast and for BRCA carriers, and is one of the most important interventions we have at the current time. However, this procedure comes with a price, so it's extremely important that clinicians work with women to help alleviate symptoms."

The new study surveyed 637 women with BRCA1 or BRCA2 mutations who had undergone the risk-reducing surgical procedure to have both ovaries and Fallopian tubes removed. Domchek and colleagues assessed participant quality-of-life through a series of questionnaires. Results show that suboptimal scores were present in the majority of patients for the majority of measures. Specifically, 73 percent reported , such as the absence of satisfaction and presence of pain; 61 percent had problems sleeping; 57 percent had symptoms of menopause such as hot flashes and vaginal dryness; and 56 percent had elevated levels of stress. Hormone replacement therapy did help mitigate symptoms, particularly in women undergoing oophorectomy prior to age 50.

Currently, it is recommended that BRCA1/2 mutation carriers undergo oophorectomy between ages 35-40 given the substantial benefits in decreasing breast and ovarian cancer risk and improving overall survival. "Our work highlights the need for novel strategies to prevent breast and ovarian cancer. Despite the efficacy of oophorectomy, given the negative impact, we need to continue to strive towards other options for prevention."

Explore further: Study shows breastfeeding, birth control may reduce ovarian cancer risk in women with BRCA mutations

Related Stories

Study shows breastfeeding, birth control may reduce ovarian cancer risk in women with BRCA mutations

May 14, 2014
Breastfeeding, tubal ligation – also known as having one's "tubes tied" – and oral contraceptives may lower the risk of ovarian cancer for some women with BRCA gene mutations, according to a comprehensive analysis from ...

Preventive oophorectomy reduces risk of death by 77 percent for women with BRCA mutation

February 25, 2014
Women who carry a BRCA gene mutation and opt for a preventive oophorectomy, or ovary removal surgery, have a 77 per cent lower risk of death than those who do not, according to a new study led by Women's College Hospital's ...

Women with BRCA mutations can take hormone-replacement therapy safely after ovary removal

June 1, 2011
Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of ...

More women removing ovaries to prevent cancer

June 25, 2013
Ovarian cancer can be a death sentence for many women. It is difficult to treat and often goes undetected until the late stages when it has spread to other organs in the pelvis and abdomen.

Prophylactic options compared for women with BRCA1/2

December 27, 2012
(HealthDay)—The results of a simulation model suggest that, when quality of life is considered, prophylactic bilateral salpingectomy with delayed oophorectomy may be an acceptable alternative to bilateral salpingo-oophorectomy ...

Recommended for you

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Physical activity could combat fatigue, cognitive decline in cancer survivors

July 25, 2017
A new study indicates that cancer patients and survivors have a ready weapon against fatigue and "chemo brain": a brisk walk.

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.